GLPwatch
In adults with T2D and ASCVD, tirzepatide was noninferior to dulaglutide for a composite CV outcome at a median 4 y.
Ann Intern Med · 2026
Last updated 2026-07-23| Journal | Ann Intern Med, 2026 |
|---|---|
| Citations | 0 |
| Molecules | tirzepatide, dulaglutide |
Abstract
GIM/FP/GP:[Formula: see text] Cardiology:[Formula: see text] Endocrinology:[Formula: see text].
Verbatim abstract via PubMed 42081805 ↗
Related research
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
- Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
- Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.